This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through November 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV
by Zacks Equity Research
Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.
MIRMNegative Net Change COLLPositive Net Change VCELNegative Net Change AMRXNegative Net Change
biotechs
Will HALO's Partner Royalties Drive Growth for the Rest of 2026?
by Kanishka Das
Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.
HALONegative Net Change RHHBYNegative Net Change JNJPositive Net Change ARGXPositive Net Change
biotechs
Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings
by Sundeep Ganoria
IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.
IONSNegative Net Change AZNNegative Net Change ALNYNegative Net Change
biotechs medical pharmaceuticals
Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
by Ahan Chakraborty
NVO's Wegovy pill generated DKK 5.4 billion in Q3 sales, boosting obesity growth amid expanding global access and intensifying GLP-1 competition.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
by Zacks Equity Research
TGTX, BCRX, INSM and MDGL are expanding commercial reach through rising therapy sales, broader patient access and potential new indications.
BCRXPositive Net Change INSMNegative Net Change TGTXNegative Net Change MDGLNegative Net Change
biotechs
Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction
by Zacks Equity Research
Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.
BAYRYNegative Net Change REGNNegative Net Change JNJPositive Net Change
biotechnology biotechs medical pharmaceuticals
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
by Zacks Equity Research
TG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.
TGTXNegative Net Change HALONegative Net Change COLLPositive Net Change AMRXNegative Net Change
biotechs earnings
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
by Zacks Equity Research
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
CRMDNegative Net Change TGTXNegative Net Change HRTXNegative Net Change AMRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
by Ahan Chakraborty
TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
BCRXPositive Net Change INSMNegative Net Change TGTXNegative Net Change MDGLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
by Sundeep Ganoria
MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.
MRNANegative Net Change SNYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical messenger-rna pharmaceuticals utilities